Hutchison MediPharma Begins Trial of Lymphoma/Leukemia Drug

Hutchison MediPharma (Chi-Med) has begun a Phase I trial of HMPL-523, an immune system suppressant, in patients with hematological malignancies. HMPL-523 is a small molecule oral inhibitor of Syk, a key component in B-cell receptor signaling. In late 2015, Hutchison MediPharma successfully completed an initial Phase I trial of HMPL-523 in healthy volunteers, with the goal of testing the molecule as a treatment for rheumatoid arthritis. Hutchison MediPharma is a subsidiary of Hutchison China MediTech Limited. More details.... Stock Symbol: (AIM: HCM) Share this with colleagues: // //